OncoSec Medical (OTC:ONCS), developer of therapies to treat solid tumor cancers, said Monday biotech publication BioWorld would feature a profile on the company and its pipeline of oncology medical system therapies.
"We are pleased to receive recognition from a global biotech publication for OncoSec's lead pipeline immunotherapeutic product,” said CEO, Punit Dhillon.
The company said it plans to report more progress from it phase two skin cancer trials in the fourth quarter.
OncoSec spun-out from Inovio Pharmaceuticals in March. The move allowed Inovio to focus on DNA vaccines, while giving OncoSec the opportunity to develop electrochemical and cytokine-based immune therapies for treating solid tumors via electroporation delivery.
Reno, Nevada-based OncoSec develops ElectroOncology therapies combing its electroporation delivery technology, with a chemotherapeutic or DNA-based immunotherapeutics.
According to the company, these therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients.